Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4086940 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Part A: LY4086940 Single Dose (Healthy Participants) | EXPERIMENTAL | Participants will receive a single dose of LY4086940 orally |
| Part A: Placebo Single Dose (Healthy Participants) | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo orally |
| Part A: LY4086940 Multiple Dose (Healthy Participants) | EXPERIMENTAL | Participants will receive LY4086940 orally for 3 days |
| Part A: Placebo Multiple Dose (Healthy Participants) | PLACEBO_COMPARATOR | Participants will receive placebo orally for 3 days |
| Part B: LY4086940 Multiple Dose (Participants with Overweight or Obesity) | EXPERIMENTAL | Participants will receive LY4086940 orally for 4 weeks |
| Part B: Placebo Multiple Dose (Participants with Overweight or Obesity) | PLACEBO_COMPARATOR | Participants will receive placebo orally for 4 weeks |
| Part C: LY4086940 Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity) | EXPERIMENTAL | Participants will receive LY4086940 orally for 4 weeks |
| Part C: Placebo Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity | PLACEBO_COMPARATOR | Participants will receive placebo orally for 4 weeks |
| Part D: LY4086940 Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity) | EXPERIMENTAL | Participants will receive LY4086940 orally for 4-6 weeks |
| Part D: Placebo Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity) | PLACEBO_COMPARATOR | Participants will receive placebo orally for 4-6 weeks |
| Part E (Open-Label): LY4086940 Single Dose (Healthy Participants) | EXPERIMENTAL | Participants will receive a single dose of LY4086940 intravenously (IV) |
| Name | Type | Description |
|---|---|---|
| LY4086940 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have no significant body weight change for the 3 months prior to screening Part A and Part E: * Are considered healthy * Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening Part B: * Have a BMI of 27 to 45 kg/m2 at screening Part C: *...
LY4086940 is an investigational small molecule developed by Eli Lilly and Company for overweight and obesity. It is in Phase 1 clinical development and has been studied in a single completed trial that enrolled 219 participants. It is not an approved medicine.
LY4086940 is being developed for overweight and obesity, a metabolic condition. The Phase 1 trial also enrolled participants with obesity and type 2 diabetes, as well as healthy participants. Because the drug is still investigational, it is not available as a treatment outside of clinical research.
LY4086940 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program studying the compound in overweight and obesity.
LY4086940 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound is investigational and has not been approved by the FDA for any indication.
LY4086940 has been studied in one Phase 1 trial, NCT06945419, titled A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes. That trial is completed, was randomized, double-blind, and placebo-controlled, enrolled 219 participants, and ran in the United States and Singapore.